Skip to main content

Table 1 Clinical profile of patients

From: Quantitative characterization of myocardial infarction by cardiovascular magnetic resonance predicts future cardiovascular events in patients with ischemic cardiomyopathy

  All (n = 86) Revascularization (n = 35) No Revascularization (n = 51) p-value
Age, years 57 ± 12 58 ± 11 57 ± 14 0.32
Gender, male 73 (85%) 32 (91%) 41 (80%) 0.16
History of hypertension 54 (63%) 26 (74%) 28 (55%) 0.07
History of HL 59 (69%) 25 (71%) 34 (67%) 0.64
History of diabetes 24 (28%) 11 (31%) 13 (25%) 0.55
History of smoking 26 (30%) 12 (34%) 14 (27%) 0.50
Beta Blocker Use 62 (78%) 27 (90%) 35 (71%) 0.06
Ace-I or ARB Use 45 (57%) 17 (57%) 28 (57%) 0.36
Coronary anatomy, n (%)     
1 vessel disease 13 (15%) 3 (9%) 10 (20%) 0.16
2 vessels disease† 24 (28%) 7 (21%) 17 (33%) 0.17
3 vessels disease 49 (57%) 25 (71%) 24 (47%) 0.02
ICD placement (%) 31 (36%) 8 (23%) 24 (47%) 0.02
Scar volume (cm3) 13.7 ± 12.7 14.5 ± 12.0 13.1 ± 13.3 0.60
Scar % of myocardium (%) 8.3 ± 6.9 9.2 ± 7.6 7.8 ± 6.3 0.37
LVEF (%) 26 ± 12 29 ± 13 24 ± 11 0.10
LVEDV (ml%) 231 ± 83 230 ± 97 232 ± 73 0.88
LVESV (ml%) 177 ± 83 173 ± 96 180 ± 74 0.69
LVED mass/volume (g/ml) 0.79 ± 0.30 0.83 ± 0.28 0.77 ± 0.31 0.22
Ant, sep infarct lesion 55 (64%) 23 (66%) 32 (63%) 0.78
Lat infarct lesion 40 (47%) 16 (46%) 24 (47%) 0.53
Inf infarct lesion 63 (73%) 25 (71%) 38 (75%) 0.75
Cardiovascular events 33 (38%) 16 (46%) 17 (33%) 0.24
  1. Values are expressed as a mean ± SD. HL = hypercholesterolemia;
  2. Ace-I = Angiotensin Converting Enzyme – Inhibitor, ARB = Angiotensin Receptor Blocker ICD = implantable cardiac defibrillator; LVEF = left ventricular ejection fraction;
  3. LVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume;
  4. † 2 vessel disease include P-LAD or LMT.